Is 1mg of Wegovy a strong dose — and what should you expect from it?

What the licensed schedule tells you about 1mg

Wegovy's approved titration pathway in the UK runs in roughly four-weekly steps: 0.25mg, then 0.5mg, then 1mg, then 1.7mg, then 2.4mg as the standard maintenance dose. The NHS medicines page for semaglutide sets this out clearly. So 1mg is a mid-ladder dose, genuinely past the tolerability-only phase, but short of the dose that produced the headline results in clinical trials.

That matters because the evidence base is built around the full maintenance dose. In the STEP 1 trial, participants using semaglutide 2.4mg weekly saw an average body-weight reduction of around 15% over 68 weeks. The 1mg step is not where those numbers were measured; it is a necessary bridge to get there safely. Calling it strong or weak in isolation misses the point: it is the right dose for the moment you are in, if that is where your prescriber has you.

One thing worth knowing is that Wegovy does now have a higher option. The MHRA approved a 7.2mg maintenance dose in early 2026, and the strongest available dose of Wegovy has shifted accordingly. That makes 1mg look even more firmly like a mid-journey checkpoint rather than a ceiling.

Why the titration pace shapes the outcome more than any single dose

The reason doses escalate slowly is almost entirely about tolerability. Nausea, loose stools and indigestion are the most common side effects of semaglutide, and they are most pronounced when the dose rises quickly. Moving through 0.5mg and 1mg before reaching 1.7mg gives the gut time to adapt. Most people find the GI symptoms settle within a couple of weeks of each step up.

This means arriving at 1mg after a month at 0.5mg is a very different experience from jumping there from scratch. The dose number is less meaningful than the trajectory. If your body is tolerating 1mg well, the prescriber's attention shifts to what comes next. If side effects are significant, they may extend the time at this dose before moving on.

People sometimes ask whether staying at 1mg permanently is an option. It can be, in exceptional circumstances, if higher doses are not tolerated, but that is a prescriber's call based on your specific picture, not something to decide unilaterally. Our guide to Wegovy doses walks through the full schedule and what each step involves.

How does 1mg compare to the doses above and below it?

The decision frame here is simpler than it looks. Below 1mg (at 0.25mg and 0.5mg) the primary goal is adjustment, not significant weight loss. Those early doses reduce the shock to your system. Whether 0.5mg feels strong depends largely on how long someone has been on it and what they were expecting.

Above 1mg, at 1.7mg, the appetite suppression becomes more consistent for most people. What 1.7mg delivers is closer to what the maintenance phase is designed to achieve. And 2.4mg is where the weight-loss evidence is strongest.

So is 1mg strong? Stronger than what came before it, yes. Strong enough to stay at indefinitely? Only if that is the clinical recommendation for you. The right comparison is not between doses in the abstract, it is between where you started and where you are going.

For a fuller picture of what private Wegovy treatment looks like through a regulated service, the Wegovy overview on our site covers licensing, eligibility and what clinical assessment involves. On costs, our guide to buying Wegovy online explains what a legitimate private prescription should include, consultation, clinical review and aftercare, not just the pen itself.

When your prescription is filled and dispatched, the pen arrives via DPD in plain, unbranded packaging, trackable on your phone, refrigerated-ready, no indication of what is inside. That part is straightforward. The clinical part (deciding when and whether to move beyond 1mg) is where a real prescriber's judgement matters most.

When to talk to your prescriber rather than searching for the answer

There are several situations where the question of dose strength needs a clinical conversation, not a web page. If you have been at 1mg for four weeks or more and are experiencing persistent nausea, it is worth raising whether the step-up should be delayed. If you are barely noticing any effect on appetite, that is also worth discussing, some people metabolise semaglutide differently, and prescribers account for that.

The NICE appraisal of semaglutide (TA875) recommends reviewing whether to continue treatment after six months at the maintenance dose if weight loss is less than 5%. That clinical review gate is built into the licensed pathway. At 1mg you are not yet at that point, but understanding the framework helps set realistic expectations.

Pregnancy, breastfeeding and actively trying to conceive are all situations where Wegovy is not recommended, at any dose. The same applies to under-18s. If your health situation has changed since starting treatment, those changes belong in a conversation with your prescriber, not a dose adjustment made independently.

If you are new to Wegovy or considering it, you can start a free consultation with our team, a named, GPhC-registered prescriber reads every submission, and any treatment is only approved when it is clinically appropriate for you.